Article citationsMore>>

I. Maruyama, “Recombinant Thrombomodulin and Activated Protein C in the Treatment of Disseminated Intravascular Coagulation,” Thrombosis and Haemostasis, Vol. 82, No. 2, 1999, pp. 718-721.

has been cited by the following article:

• TITLE: Successful Treatment of Life-Threatening Cerebral Bleeding Associated with Disseminated Intravascular Coagulation Using Recombinant Human Soluble Thrombomodulin in a Patient with Mixed Phenotype Acute Leukemia with t (9; 22) (q34; q11.2); Bcr-Abl1

  AUTHORS: Naoki Takezako, Takashi Ishii, Akihisa Nagata, Naohiro Sekiguchi, Satoshi Noto, Akiyoshi Miwa

  KEYWORDS: Mixed Phenotype Acute Leukemia with t (9; 22) (q34; q11.2); Bcr-Abl1; Recombinant Human Soluble Thrombomodulin; Imatinib; Disseminated Intravascular Coagulation

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.4 No.1, January 29, 2013

  ABSTRACT: Recently, mixed phenotype acute leukemia (MPAL) with t (9; 22) (q34; q11.2); bcr-abl1 was described as one kind of acute leukemia of ambiguous lineage in the 2008 World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. However, treatment strategy remains difficult for this uncommon MPAL. In addition, this type of MPAL is at high risk of tumor lysis syndrome (TLS) because of high chemo-sensitivity. Here, we report a MPAL with t (9; 22) (q34; q11.2); bcr-abl1 case that suffered from life-threatening cerebral bleeding associated with disseminated intravascular coagulation (DIC) with TLS after bcr-abl positive acute lymphoblastic leukemia (ALL) type induction therapy who was successfully treated with recombinant human thrombomodulin (rhTM). This case reached complete remission without additive cerebral bleeding. In conclusion, bcr-abl positive ALL type induction therapy was effective for MPAL with t (9; 22) (q34; q11.2); bcr-abl1 and rhTM was effective against DIC with TLS.